Fluconazole versus an echinocandin for Candida glabrata fungaemia: A retrospective cohort study

Journal of Antimicrobial Chemotherapy

Volumn 68, Issue 4, 2013, Pages 922-926

  Eschenauer, Gregory A ^a   Carver, Peggy L ^b   Lin, Shu Wen ^c   Klinker, Kenneth P ^d   Chen, Yee Chun ^e   Potoski, Brian A ^f   Shields, Ryan K ^g   Clancy, Cornelius J ^g   Nguyen, Minh Hong ^g   Lam, Simon W ^h  

^a UNIVERSITY OF PITTSBURGH MEDICAL CENTER   (United States)

^b UNIVERSITY OF MICHIGAN   (United States)

^c NATIONAL TAIWAN UNIVERSITY   (Taiwan)

^d UNIVERSITY OF FLORIDA   (United States)

^e NATIONAL TAIWAN UNIVERSITY HOSPITAL   (Taiwan)

^f UNIVERSITY OF PITTSBURGH   (United States)

^g UNIVERSITY OF PITTSBURGH SCHOOL OF MEDICINE   (United States)

^h LERNER RESEARCH INSTITUTE   (United States)

Author keywords

Breakpoints; ICU; Pharmacodynamics

Indexed keywords

ECHINOCANDIN; FLUCONAZOLE;

ADULT; ARTICLE; CANDIDA GLABRATA; CANDIDIASIS; DRUG TREATMENT FAILURE; FEMALE; FUNGUS CULTURE; FUNGUS GROWTH; HUMAN; INTENSIVE CARE UNIT; MAJOR CLINICAL STUDY; MALE; MINIMUM INHIBITORY CONCENTRATION; MORTALITY; MULTICENTER STUDY; NONHUMAN; PHARMACODYNAMICS; RETROSPECTIVE STUDY; SURVIVAL; TREATMENT OUTCOME; TREATMENT RESPONSE;

ADULT; AGED; AGED, 80 AND OVER; ANTIFUNGAL AGENTS; CANDIDA GLABRATA; CANDIDEMIA; COHORT STUDIES; ECHINOCANDINS; FEMALE; FLUCONAZOLE; HUMANS; MALE; MIDDLE AGED; RETROSPECTIVE STUDIES; SURVIVAL ANALYSIS; TREATMENT OUTCOME;

EID: 84875268251     PISSN: 03057453     EISSN: 14602091     Source Type: Journal    
DOI: 10.1093/jac/dks482     Document Type: Article

References (16)

1. Wisplinghoff H, Bischoff T, Tallent SM et al. Nosocomial bloodstream infections in US hospitals: analysis of 24,179 cases from a prospective nationwide surveillance study. Clin Infect Dis 2004; 39: 309-17.
2. Andes DR, Safdar N, Baddley JWet al. Impact of treatment strategy on outcomes in patients with candidemia and other forms of invasive candidiasis: a patient-level quantitative review of randomized trials. Clin Infect Dis 2012; 54: 1110-22.
3. Reboli AC, Rotstein C, Pappas PG et al. Anidulafungin versus fluconazole for invasive candidiasis. N Engl J Med 2007; 356: 2472-82.
4. Pappas PG, Kauffman CA, Andes D et al. Clinical practice guidelines for the management of candidiasis: 2009 update by the Infectious Diseases Society of America. Clin Infect Dis 2009; 48: 503-35.
5. Horn DL, Neofytos D, Anaissi EJ et al. Epidemiology and outcomes of candidemia in 2019 patients: data from the prospective antifungal therapy alliance registry. Clin Infect Dis 2009; 48: 1695-703.
6. MacCallum DM. Hosting infection: experimental models to assay Candida virulence. Int J Microbiol 2012; 2012: 363764.
7. Pfaller MA, Diekema DJ. Epidemiology of invasive candidiasis: a persistent public health problem. Clin Microbiol Rev 2007; 20: 133-63.
8. Thom KA, Shardell MD, Osih RB et al. Controlling for severity of illness in outcome studies involving infectious diseases: impact of measurement at different time points. Infect Control Hosp Epidemiol 2008; 29: 1048-53.
9. Knaus WA, Draper EA, Wagner DP et al. APACHE II: a severity of disease classification system. Crit Care 1995; 13: 818-29.
10. Segal BH, Herbrecht R, Stevens DA et al. Defining responses to therapy and study outcomes in clinical trials of invasive fungal diseases: Mycoses Study Group and European Organization for Research and Treatment of Cancer consensus criteria. Clin Infect Dis 2008; 47: 674-83.
11. Pfaller MA, Diekema DJ, Sheehan DJ. Interpretive breakpoints for fluconazole and Candida revisited: a blueprint for the future of antifungal susceptibility testing. Clin Microbiol Rev 2006; 19: 435-47.
12. Cockcroft DW, Gault MH. Prediction of creatinine clearance from serum creatinine. Nephron 1976; 16: 31-41.
13. Garey KW, Pai MP, Suda KJ et al. Inadequacy of fluconazole dosing in patients with candidemia based on Infectious Diseases Society of America (IDSA) guidelines. Pharmacoepidemiol Drug Saf 2007; 16: 919-27.
14. Pai M, Turpin RS, Garey KW. Association of fluconazole area under the concentration-time curve/MIC and dose/MIC ratios with mortality in nonneutropenic patients with candidemia. Antimicrob Agents Chemother 2007; 51: 35-9.
15. Baddley JW, Patel M, Bhavnani SM et al. Association of fluconazole pharmacodynamics with mortality in patients with candidiemia. Antimicrob Agents Chemother 2008; 52: 3022-8.
16. Pfaller MA, Andes D, Diekema DJ et al. Wild-type MIC distributions, epidemiological cutoff values and species-specific clinical breakpoints for fluconazole and Candida: time for harmonization of CLSI and EUCAST broth microdilution methods. Drug Resist Updat 2010; 13: 180-95.